Pfizer Inc.
Pfizer Inc. Fundamental Analysis
Pfizer Inc. (PFE) shows moderate financial fundamentals with a PE ratio of 19.43, profit margin of 12.42%, and ROE of 8.52%. The company generates $62.6B in annual revenue with moderate year-over-year growth of 6.84%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 45.9/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PFE's fundamental strength across five key dimensions:
Efficiency Score
WeakPFE struggles to generate sufficient returns from assets.
Valuation Score
ExcellentPFE trades at attractive valuation levels.
Growth Score
ModeratePFE shows steady but slowing expansion.
Financial Health Score
ModeratePFE shows balanced financial health with some risks.
Profitability Score
WeakPFE struggles to sustain strong margins.
Key Financial Metrics
Is PFE Expensive or Cheap?
P/E Ratio
PFE trades at 19.43 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, PFE's PEG of -0.91 indicates potential undervaluation.
Price to Book
The market values Pfizer Inc. at 1.62 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 10.01 times EBITDA. This signals the market has high growth expectations.
How Well Does PFE Make Money?
Net Profit Margin
For every $100 in sales, Pfizer Inc. keeps $12.42 as profit after all expenses.
Operating Margin
Core operations generate 24.67 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $8.52 in profit for every $100 of shareholder equity.
ROA
Pfizer Inc. generates $0.00 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Pfizer Inc. produces operating cash flow of $6.36B, showing steady but balanced cash generation.
Free Cash Flow
Pfizer Inc. produces free cash flow of $4.57B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.80 in free cash annually.
FCF Yield
PFE converts 3.02% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
19.43
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.91
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.62
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.41
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.00
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.09
vs 25 benchmark
ROA
Return on assets percentage
0.00
vs 25 benchmark
ROCE
Return on capital employed
0.00
vs 25 benchmark
How PFE Stacks Against Its Sector Peers
| Metric | PFE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 19.43 | 29.43 | Better (Cheaper) |
| ROE | 8.52% | 800.00% | Weak |
| Net Margin | 12.42% | -20145.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 0.00 | 4.64 | Weak Liquidity |
| ROA | 0.00% | -17936.00% (disorted) | Weak |
PFE outperforms its industry in 3 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Pfizer Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
51.95%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-51.54%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-0.46%
Industry Style: Defensive, Growth, Innovation
Declining